Skip to content

Heerbal Approach To Arthritis Unani Formulation Shows Promise In knee Pain Management

Comparative Evaluation Of Efficacy Of The Unani Polyherbal Formulation And Habb Suranjan In Waja Al Mafasil(Knee Osteoarthritis)-A Randomized Clinical Trial - NIL

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/06/089381
Enrollment
60
Registered
2025-06-23
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M170- Bilateral primary osteoarthritis of knee

Interventions

Intervention1: Unani Polyherbal Formulation Hulba (Trigonella foenum-graecum), Ajwain (Tachyspermum Ammi), Haloon (Lepidium sativum Linn), and Kalonji (nigella sativa): Equal quantity of all drugs in

Sponsors

Government Of Tamilnadu
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Radiological changes as per grades I to IV of the Kellgren and Lawrence Radiological scale. Patients of OA Knee Joint as per ACR Criteria The presence of knee pain with at least one of the following three items along with osteophyte in knee X-ray can classify the knee OA in the patients 30 years and above Morning stiffness less than 30 minutes Crepitus on knee motion. Willing to comply with the protocol

Exclusion criteria

Exclusion criteria: Participants age below 30 years and above 65 years. Intervention concerning History of any Trauma/Fractured joint/Surgical/Knee replacement/intra articular injections. Any unstable cardiovascular disease, chronic systemic illness, and any evidence of malignancy. Other types of osteoarthritis Rheumatoid arthritis, etc. Pregnant and lactating women. Mentally unstable patients. Participants who are currently participating in any other clinical trial.

Design outcomes

Primary

MeasureTime frame
To assess the efficacy of the Unani test drug with the well-validated WOMAC CRD PUNE and VAS scale.Timepoint: Baseline, 1st week ,2nd week, 4thweek , 6th week

Secondary

MeasureTime frame
Improvement in QOL with WOMAC(Modified)CRD PUNE in OA patients from baseline to 6 weeks.Timepoint: Baseline, 1st week ,2nd week, 4thweek , 6th week

Countries

India

Contacts

Public ContactDr Mubasheera Begum

Government Unani Medical College

muskaan.m@gmail.com9841620486

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026